We have extensive M&A experience, gained across continents and cultures, that we call upon to assist our clients achieve favourable business outcomes. We advise on deal structuring, acquisitions, divestments, joint ventures, and PE/VC investments.
Our prior industry experience as in-house counsel informs our approach to M&A. Our lawyers have negotiated and handled strategic pharmaceutical acquisitions worth over USD 5 Billion, including acquisitions, minority investments, joint ventures and dispositions. Our M&A experience spans every continent except Antartica. Our industry focus gives us an edge in pharmaceutical M&A, when it comes to diligence, structuring and negotiations.
Lupin on USD 510 million sale of Japanese subsidiaries
Cipla on two divestments in China, of USD 97 million and USD 18.5 million
Cipla on USD 1.5 million investment in U.S. based Alzheimer’s therapy startup
Cipla on spinning off its consumer health and biologics businesses
